Advertisement

World Journal of Surgery

, 35:2051 | Cite as

Clinical Significance of the B7-H4 Coregulatory Molecule as a Novel Prognostic Marker in Gastric Cancer

  • Takaaki ArigamiEmail author
  • Yoshikazu Uenosono
  • Sumiya Ishigami
  • Takahiko Hagihara
  • Naoto Haraguchi
  • Shoji Natsugoe
Article

Abstract

Background

The B7-H4 coregulatory molecule is a member of the B7 family of molecules, which regulate the T-cell-mediated immune response through CD28 receptors. Recently, B7-H4 has been reported to be a negative regulator of the immune response in patients with several malignant diseases. However, few reports have investigated the clinical significance of B7-H4 expression in patients with gastric cancer. In the present study, we analyzed B7-H4 expression and the relationship between its expression and clinicopathological factors including prognosis in gastric cancer.

Methods

B7-H4 expression in gastric cancer cell lines and clinical gastric cancer specimens was initially assessed with the reverse transcription-polymerase chain reaction (RT-PCR). Moreover, B7-H4 and CD3 expression in 120 resected specimens from gastric cancer patients were evaluated by immunohistochemistry (IHC).

Results

B7-H4 expression was identified in the gastric cancer cell lines and clinical tumor tissues by RT-PCR. B7-H4 expression was high in 25.8% (31/120) of resected tumor specimens. B7-H4 expression significantly correlated with tumor stage (P = 0.04). The 5-year survival rate was significantly lower in patients with high B7-H4 expression than in those with low B7-H4 expression (P = 0.001). Multivariate analysis demonstrated that B7-H4 expression was an independent prognostic factor (P = 0.035). Immunohistochemical analysis of CD3 expression showed that B7-H4 expression was inversely correlated with the number of tumor infiltrating T lymphocytes (P < 0.001).

Conclusions

The B7-H4 coregulatory molecule is a novel prognostic marker related to the T-cell-mediated immune response, and its pathway may be a molecular target for controlling tumor progression in patients with gastric cancer.

Keywords

Gastric Cancer Gastric Cancer Patient Gastric Cancer Cell Line Resected Primary Tumor Primary Tumor Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

This work was supported in part by a grant-in-aid (no. 22791256) for scientific research from the Ministry of Education, Science, Sports, and Culture, Japan. The authors are grateful to Y. Nishizono and A. Harada for technical assistance.

Conflict of interest

None.

References

  1. 1.
    Statistics and Information Department, Ministry of Health, Labour, and Welfare (2006) Vital statistics of Japan 2004. Health and Welfare Statistics Association, TokyoGoogle Scholar
  2. 2.
    Katanoda K, Yako-Suketomo H (2009) Comparison of time trends in stomach cancer incidence (1973–2002) in Asia, from Cancer Incidence in Five Continents, Vols IV–IX. Jpn J Clin Oncol 39:71–72PubMedCrossRefGoogle Scholar
  3. 3.
    Li ZX, Kaminishi M (2009) A comparison of gastric cancer between Japan and China. Gastric Cancer 12:52–53PubMedCrossRefGoogle Scholar
  4. 4.
    Sakuramoto S, Sasako M, Yamaguchi T et al (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810–1820PubMedCrossRefGoogle Scholar
  5. 5.
    Sim SH, Kim YJ, Oh DY et al (2009) The role of PET/CT in detection of gastric cancer recurrence. BMC Cancer 9:73PubMedCrossRefGoogle Scholar
  6. 6.
    Flies DB, Chen L (2006) Modulation of immune response by B7 family molecules in tumor microenvironments. Immunol Invest 35:395–418PubMedCrossRefGoogle Scholar
  7. 7.
    Flies DB, Chen L (2007) The new B7s: playing a pivotal role in tumor immunity. J Immunother 30:251–260PubMedCrossRefGoogle Scholar
  8. 8.
    Zang X, Allison JP (2007) The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res 13:5271–5279PubMedCrossRefGoogle Scholar
  9. 9.
    Sica GL, Choi IH, Zhu G et al (2003) B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 18:849–861PubMedCrossRefGoogle Scholar
  10. 10.
    Prasad DV, Richards S, Mai XM et al (2003) B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity 18:863–873PubMedCrossRefGoogle Scholar
  11. 11.
    Zang X, Loke P, Kim J et al (2003) B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci USA 100:10388–10392PubMedCrossRefGoogle Scholar
  12. 12.
    Tringler B, Zhuo S, Pilkington G et al (2005) B7-H4 is highly expressed in ductal and lobular breast cancer. Clin Cancer Res 11:1842–1848PubMedCrossRefGoogle Scholar
  13. 13.
    Salceda S, Tang T, Kmet M et al (2005) The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation. Exp Cell Res 306:128–141PubMedCrossRefGoogle Scholar
  14. 14.
    Simon I, Zhuo S, Corral L et al (2006) B7-H4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Cancer Res 66:1570–1575PubMedCrossRefGoogle Scholar
  15. 15.
    Sun Y, Wang Y, Zhao J et al (2006) B7–H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer 53:143–151PubMedCrossRefGoogle Scholar
  16. 16.
    Krambeck AE, Thompson RH, Dong H et al (2006) B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci USA 103:10391–10396PubMedCrossRefGoogle Scholar
  17. 17.
    Simon I, Katsaros D, Rigault de la Longrais I et al (2007) B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression. Gynecol Oncol 106:334–341PubMedCrossRefGoogle Scholar
  18. 18.
    Kryczek I, Wei S, Zhu G et al (2007) Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res 67:8900–8905PubMedCrossRefGoogle Scholar
  19. 19.
    Zheng Y, Katsaros D, Shan SJ et al (2007) A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy. Clin Cancer Res 13:6984–6992PubMedCrossRefGoogle Scholar
  20. 20.
    Miyatake T, Tringler B, Liu W et al (2007) B7-H4 (DD-O110) is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration. Gynecol Oncol 106:119–127PubMedCrossRefGoogle Scholar
  21. 21.
    Awadallah NS, Shroyer KR, Langer DA et al (2008) Detection of B7-H4 and p53 in pancreatic cancer: potential role as a cytological diagnostic adjunct. Pancreas 36:200–206PubMedCrossRefGoogle Scholar
  22. 22.
    Arigami T, Uenosono Y, Hirata M et al (2010) Expression of B7-H4 in blood of patients with gastric cancer predicts tumor progression and prognosis. J Surg Oncol 102:748–752PubMedCrossRefGoogle Scholar
  23. 23.
    Arigami T, Natsugoe S, Uenosono Y et al (2005) Lymphatic invasion using D2-40 monoclonal antibody and its relationship to lymph node micrometastasis in pN0 gastric cancer. Br J Cancer 93:688–693PubMedCrossRefGoogle Scholar
  24. 24.
    Arigami T, Natsugoe S, Uenosono Y et al (2006) Evaluation of sentinel node concept in gastric cancer based on lymph node micrometastasis determined by reverse transcription-polymerase chain reaction. Ann Surg 243:341–347PubMedCrossRefGoogle Scholar
  25. 25.
    Edge SB, Byrd DR, Compton CC et al (2010) American Joint Committee on Cancer (AJCC) cancer staging manual, 7th edn. Springer, New YorkGoogle Scholar
  26. 26.
    Hsu SM, Raine L, Fanger H (1981) Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29:577–580PubMedCrossRefGoogle Scholar
  27. 27.
    Sun J, Chen LJ, Zhang GB et al (2010) Clinical significance and regulation of the costimulatory molecule B7-H3 in human colorectal carcinoma. Cancer Immunol Immunother 59:1163–1171PubMedCrossRefGoogle Scholar
  28. 28.
    Choi IH, Zhu G, Sica GL et al (2003) Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. J Immunol 171:4650–4654PubMedGoogle Scholar
  29. 29.
    Oikonomopoulou K, Li L, Zheng Y et al (2008) Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel. Br J Cancer 99:1103–1113PubMedCrossRefGoogle Scholar
  30. 30.
    Jiang J, Zhu Y, Wu C et al (2010) Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer. Cancer Immunol Immunother 59:1707–1714PubMedCrossRefGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2011

Authors and Affiliations

  • Takaaki Arigami
    • 1
    Email author
  • Yoshikazu Uenosono
    • 1
  • Sumiya Ishigami
    • 1
  • Takahiko Hagihara
    • 1
  • Naoto Haraguchi
    • 1
  • Shoji Natsugoe
    • 1
  1. 1.Department of Surgical Oncology and Digestive Surgery, Field of Oncology, Course of Advanced TherapeuticsKagoshima University Graduate School of Medical and Dental SciencesKagoshimaJapan

Personalised recommendations